3Takahashi S. Evaluation of cancer-induced bone diseases by bone metabolic marker[ J ]. Clin Calcium, 2006, 16(4 ) :49-58.
4Kong QQ, Sun TW, Dou QY, et al. Beta-CTX and ICTP act as indicators of skeletal metastasis status in male patients with non- small cell lung cancer[J]. Int J Biol Markers, 2007, 22(3) : 214-220.
5Koopmans N, de Jong I J, Breeuwsma A J, et al. Serum bone turnover markers ( PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach[J]. J Urol, 2007, 178(3) :849-853.
6Maemura M, Iino Y, Yokoe T, et al. Serum concentration of pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with metastatic breast cancer [ J ]. Oncol Rep, 2000, 7(6) :1333-1338.
7Chrapko BE, Nocun A, Goebiewska R, et al. Bone turnover markers and bone scintigraphy in the evaluation of the skeletal metastases[J]. Nucl Med Rev Cent East Eur, 2005, 8(2): 100-104.
8Voorzanger-Rousselot N, Juillet F, Mareau E. Association of 12 serum biochemical markers of angiogenesis, turnout invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation [ J ]. Br J Cancer, 2006, 95 (4) :506-514.
9Ebert W, Muley T, Herb KP, et al. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients [ J ]. Anticancer Res, 2004, 24 (5 B ) : 3193-3201.
10Zissimopoulos A, Petrakis G, Stellos K,et al, Procollagen-I, collagen telopeptide I, CEA, CA15-3 as compared to bone scintigraphy in patients with breast cancer [ J ]. Hell J Nucl Med, 2006, 9(1) :60-64.
二级参考文献4
1Wilson MA,Calhoun FW.The distribution of skeletal metastases in breast and pulmonary cancer:concise communication[J].J Nucl Med,1981,22:594.
